https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/
Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).
hoffmann la rochechronic lymphocyticobinutuzumabrefractory
https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-graft-versus-host-disease-gvhd-likelihood-of-approval/
Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Graft Versus Host Disease (GVHD).
hoffmann la rochegraft versus hostobinutuzumab